SHPH · Shuttle Pharmaceuticals Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company’s existing cash resources, the cash received from the equity offerings, and financing available under the revolving note are not expected to provide sufficient funds to carry out the Company’s operations through the next twelve months. The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully raise additional equity or debt financing to allow it to fund ongoing operations, fund milestone and contingent payments due under the APA, and commercialize and market the Molecule.ai platform in order to generate revenues. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 11, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 11, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SHPH
this stock
Shuttle Pharmaceuticals Holdings, Inc.
|
$2.06M | — | — | — | 9.6% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.25B | +17.0% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.91B | +2.5% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.98B | +0.5% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 17.8%
- Net QoQ
- +88.3K sh
- Top holder
- HRT FINANCIAL LP
Performance
Raw-price comparisons begin at the captured split on Jun 11, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SHPH | -14.2% | +20.6% | — | -7.4% | — |
| SPY | -1.2% | +3.3% | +12.2% | +2.2% | +12.0% |
| vs SPY | -13.0% | +17.3% | — | -9.6% | — |